,
Clinical Department of Gynaecology and Obstetrics, University Hospital Centre Osijek , Osijek , Croatia
School of Medicine, J.J. Strossmayer University , Osijek , Croatia
School of Medicine, J.J. Strossmayer University , Osijek , Croatia
Department of Medical Chemistry, Biochemistry and Clinical Chemistry, University Hospital Centre , Osijek , Croatia
Clinical Department of Gynaecology and Obstetrics, University Hospital Centre Osijek , Osijek , Croatia
School of Medicine, J.J. Strossmayer University , Osijek , Croatia
School of Medicine, J.J. Strossmayer University , Osijek , Croatia
Department of Medical Chemistry, Biochemistry and Clinical Chemistry, University Hospital Centre , Osijek , Croatia
School of Medicine, J.J. Strossmayer University , Osijek , Croatia
Department of Medical Chemistry, Biochemistry and Clinical Chemistry, University Hospital Centre , Osijek , Croatia
Clinical Department of Gynaecology and Obstetrics, University Hospital Centre Osijek , Osijek , Croatia
School of Medicine, J.J. Strossmayer University , Osijek , Croatia
Aim
To investigate a potential of the clinical use of the soluble fms-like tyrosine kinase 1 (sFLT-1) to placental growth factor (PlGF) ratio from the perspective of a small hospital centre.
Methods
Maternal serum samples were analysed at 24 1/7-28 0/7 , and 28 1/7-32 0/7 weeks of gestation. The level of sFLT-1 and PIGF was determined by immunoassay platform and used to calculate the sFLT-1/PIGF ratio in 35 pregnant women, and divided into subgroups according to preeclampsia occurrence at the time of delivery: preterm (≤37 weeks) or term (37-42 weeks'), and matched a control group.
Results
Patients in the preterm delivery group had a significantly higher incidence of intrauterine growth restriction, lower gestational age at the time of delivery, and lower infant birth weight compared to the other two groups. There was a negative correlation between the sFLT-1/PlGF ratio and GA and between the sFLT-1/ PlGF ratio and birth weight at the time of delivery. The value of the sFLT-1/PlGF ratio was significantly higher in the preterm delivery PE group. All the PE group pregnancies ended with caesarean delivery compared to 25% in the control group. However, none of the patients from the PE group had any of the possible complications of preeclampsia nor did they require additional therapy such as blood transfusion or additional non-standard hypertensive therapy.
Conclusion
The sFLT-1/PlGF ratio could be used as an indicator for the development and estimation of the severity of PE to provide objective evidence for the management of preeclampsia patients, and as a predictive marker of preeclampsia at low cost.
This work is licensed under a Attribution-NonCommercial-NoDerivatives 4.0 International 
3
Min SuLiuhong Shi, Junze Bao, Xiaoqing Huo, Yu Zhu, Jiaqi Yang, Xueyan Cao,
(2023)
Levels and Significance of Arachidonic Acid Metabolites in Hypertensive Disorders of Pregnancy: A Prospective Cohort Study
Clinical and Experimental Obstetrics & Gynecology, 50(12)
10.31083/j.ceog5012263
Shanshan Tian, Libin He, Ahuang Pan, Lina Zhang, Jielin Wang
(2025)
sFlt-1/PlGF ratio combined with endocan-1 serum levels improves the predictive values for the occurrence and prognosis of preeclampsia in a single centre study
Journal of Human Hypertension, 39(5)
10.1038/s41371-025-01009-5
Jamarius P. Waller, John Aaron Howell, Hali Peterson, Eric M. George, Gene L. Bidwell
(2021)
Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia
Hypertension, 78(6)
10.1161/HYPERTENSIONAHA.121.17713The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.